• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多阶段淘汰失败者试验中所选治疗均值的条件无偏和近似无偏估计。

Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.

作者信息

Bowden Jack, Glimm Ekkehard

机构信息

MRC Biostatistics Unit, Cambridge, CB2 OSR, UK.

出版信息

Biom J. 2014 Mar;56(2):332-49. doi: 10.1002/bimj.201200245. Epub 2013 Dec 18.

DOI:10.1002/bimj.201200245
PMID:24353149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4034592/
Abstract

The two-stage drop-the-loser design provides a framework for selecting the most promising of K experimental treatments in stage one, in order to test it against a control in a confirmatory analysis at stage two. The multistage drop-the-losers design is both a natural extension of the original two-stage design, and a special case of the more general framework of Stallard & Friede () (Stat. Med. 27, 6209-6227). It may be a useful strategy if deselecting all but the best performing treatment after one interim analysis is thought to pose an unacceptable risk of dropping the truly best treatment. However, estimation has yet to be considered for this design. Building on the work of Cohen & Sackrowitz () (Stat. Prob. Lett. 8, 273-278), we derive unbiased and near-unbiased estimates in the multistage setting. Complications caused by the multistage selection process are shown to hinder a simple identification of the multistage uniform minimum variance conditionally unbiased estimate (UMVCUE); two separate but related estimators are therefore proposed, each containing some of the UMVCUEs theoretical characteristics. For a specific example of a three-stage drop-the-losers trial, we compare their performance against several alternative estimators in terms of bias, mean squared error, confidence interval width and coverage.

摘要

两阶段淘汰失败者设计提供了一个框架,用于在第一阶段从K种实验性治疗方法中选择最有前景的方法,以便在第二阶段的验证性分析中将其与对照进行比较。多阶段淘汰失败者设计既是原始两阶段设计的自然扩展,也是Stallard & Friede ()(《统计医学》27, 6209 - 6227)更一般框架的一个特殊情况。如果认为在一次中期分析后淘汰除表现最佳的治疗方法之外的所有方法会带来淘汰真正最佳治疗方法的不可接受风险,那么这可能是一种有用的策略。然而,尚未考虑该设计的估计问题。基于Cohen & Sackrowitz ()(《统计与概率快报》8, 273 - 278)的工作,我们在多阶段设置中推导了无偏和近似无偏估计。结果表明,多阶段选择过程引起的复杂性阻碍了对多阶段均匀最小方差条件无偏估计(UMVCUE)的简单识别;因此提出了两个单独但相关的估计量,每个都包含一些UMVCUE的理论特征。对于一个三阶段淘汰失败者试验的具体例子,我们在偏差、均方误差、置信区间宽度和覆盖率方面将它们的性能与几种替代估计量进行了比较。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/f04819302d6a/bimj0056-0332-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/728ca172719b/bimj0056-0332-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/9d14b0b18b55/bimj0056-0332-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/16e6b8bf8b91/bimj0056-0332-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/f04819302d6a/bimj0056-0332-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/728ca172719b/bimj0056-0332-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/9d14b0b18b55/bimj0056-0332-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/16e6b8bf8b91/bimj0056-0332-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a197/4034592/f04819302d6a/bimj0056-0332-f4.jpg

相似文献

1
Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.多阶段淘汰失败者试验中所选治疗均值的条件无偏和近似无偏估计。
Biom J. 2014 Mar;56(2):332-49. doi: 10.1002/bimj.201200245. Epub 2013 Dec 18.
2
Conditionally unbiased estimation in the normal setting with unknown variances.方差未知的正态分布下的条件无偏估计。
Commun Stat Theory Methods. 2018 Jan 5;48(3):616-627. doi: 10.1080/03610926.2017.1417429. eCollection 2019.
3
Estimation of the selected treatment mean in two stage drop-the-losers design.两阶段剔除失败者设计中选定治疗均值的估计。
J Biopharm Stat. 2024 Mar;34(2):164-189. doi: 10.1080/10543406.2023.2183962. Epub 2023 Mar 5.
4
Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.两阶段删失失败者设计中选定治疗组均数的经验 Bayes 估计:一种荟萃分析方法。
Stat Med. 2014 Feb 10;33(3):388-400. doi: 10.1002/sim.5920. Epub 2013 Jul 22.
5
Point estimation following a two-stage group sequential trial.两阶段分组序贯试验后的点估计。
Stat Methods Med Res. 2023 Feb;32(2):287-304. doi: 10.1177/09622802221137745. Epub 2022 Nov 16.
6
Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.两阶段自适应设计中基于中期治疗选择的收缩估计。
Stat Med. 2013 May 10;32(10):1677-90. doi: 10.1002/sim.5463. Epub 2012 Jun 29.
7
Adjusting for treatment selection in phase II/III clinical trials with time to event data.调整具有生存时间数据的 II/III 期临床试验中的治疗选择。
Stat Med. 2023 Jan 30;42(2):146-163. doi: 10.1002/sim.9606. Epub 2022 Nov 23.
8
Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.两阶段、有剔除失败者的临床试验中灵活治疗选择的区间估计。
Stat Med. 2011 Oct 15;30(23):2804-14. doi: 10.1002/sim.4308. Epub 2011 Aug 8.
9
Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.在具有不等治疗效果方差和假设驱动选择规则的无缝II/III期试验中的无偏估计。
Stat Med. 2016 Sep 30;35(22):3907-22. doi: 10.1002/sim.6974. Epub 2016 Apr 21.
10
Point estimation in adaptive enrichment designs.适应性富集设计中的点估计
Stat Med. 2017 Nov 10;36(25):3935-3947. doi: 10.1002/sim.7412. Epub 2017 Aug 7.

引用本文的文献

1
Confidence Intervals for Adaptive Trial Designs I: A Methodological Review.适应性试验设计的置信区间I:方法学综述
Stat Med. 2025 Aug;44(18-19):e70174. doi: 10.1002/sim.70174.
2
Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.多臂多阶段(MAMS)随机选择设计:治疗选择规则对操作特性的影响。
BMC Med Res Methodol. 2024 Jun 3;24(1):124. doi: 10.1186/s12874-024-02247-w.
3
Point estimation for adaptive trial designs I: A methodological review.自适应试验设计的点估计 I:方法学综述。

本文引用的文献

1
Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.有条件无偏估计在具有无效性提前停止的 II/III 期临床试验中。
Stat Med. 2013 Jul 30;32(17):2893-910. doi: 10.1002/sim.5757. Epub 2013 Feb 15.
2
Adaptive trial designs: a review of barriers and opportunities.适应性试验设计:障碍与机遇的综述。
Trials. 2012 Aug 23;13:145. doi: 10.1186/1745-6215-13-145.
3
Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.两阶段自适应设计中基于中期治疗选择的收缩估计。
Stat Med. 2023 Jan 30;42(2):122-145. doi: 10.1002/sim.9605. Epub 2022 Nov 30.
4
Adjusting for treatment selection in phase II/III clinical trials with time to event data.调整具有生存时间数据的 II/III 期临床试验中的治疗选择。
Stat Med. 2023 Jan 30;42(2):146-163. doi: 10.1002/sim.9606. Epub 2022 Nov 23.
5
Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.具有事件发生时间数据和生物标志物驱动的亚组选择的两阶段自适应设计中的点估计和区间估计。
Stat Med. 2020 Aug 30;39(19):2568-2586. doi: 10.1002/sim.8557. Epub 2020 May 3.
6
Estimation of treatment effects following a sequential trial of multiple treatments.多种治疗方法序贯试验后的治疗效果评估。
Stat Med. 2020 May 20;39(11):1593-1609. doi: 10.1002/sim.8497. Epub 2020 Mar 23.
7
Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.自适应无缝临床试验,使用早期结果进行治疗或亚组选择:方法、模拟模型及其在 R 中的实现。
Biom J. 2020 Sep;62(5):1264-1283. doi: 10.1002/bimj.201900020. Epub 2020 Mar 2.
8
Adaptive multiarm multistage clinical trials.自适应多臂多阶段临床试验。
Stat Med. 2020 Apr 15;39(8):1084-1102. doi: 10.1002/sim.8464. Epub 2020 Feb 11.
9
Response adaptive randomization procedures in seamless phase II/III clinical trials.无缝二期/三期临床试验中的反应适应性随机化程序。
J Biopharm Stat. 2020;30(1):3-17. doi: 10.1080/10543406.2019.1657439. Epub 2019 Aug 27.
10
Adaptive designs in clinical trials: why use them, and how to run and report them.临床试验中的适应性设计:为何使用它们,以及如何实施和报告它们。
BMC Med. 2018 Feb 28;16(1):29. doi: 10.1186/s12916-018-1017-7.
Stat Med. 2013 May 10;32(10):1677-90. doi: 10.1002/sim.5463. Epub 2012 Jun 29.
4
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.两阶段诊断性生物标志物研究后的条件估计,该研究允许因无效而提前终止。
Stat Med. 2012 Feb 28;31(5):420-35. doi: 10.1002/sim.4430. Epub 2012 Jan 12.
5
Likelihood inference for a two-stage design with treatment selection.具有治疗选择的两阶段设计的似然推断
Biom J. 2010 Dec;52(6):811-22. doi: 10.1002/bimj.200900170.
6
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.在 COPD 临床研究中使用适应性无缝设计整合茚达特罗剂量选择。
Pulm Pharmacol Ther. 2010 Jun;23(3):165-71. doi: 10.1016/j.pupt.2010.01.003. Epub 2010 Jan 18.
7
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility.来自一项2期生物标志物研究的敏感性和特异性的条件估计,该研究允许因无效而提前终止。
Stat Med. 2009 Feb 28;28(5):762-79. doi: 10.1002/sim.3506.
8
A group-sequential design for clinical trials with treatment selection.一种用于有治疗选择的临床试验的序贯分组设计。
Stat Med. 2008 Dec 20;27(29):6209-27. doi: 10.1002/sim.3436.
9
Unbiased estimation of selected treatment means in two-stage trials.两阶段试验中选定治疗均值的无偏估计。
Biom J. 2008 Aug;50(4):515-27. doi: 10.1002/bimj.200810442.
10
Testing and estimation in flexible group sequential designs with adaptive treatment selection.具有适应性治疗选择的灵活序贯组设计中的检验与估计
Stat Med. 2005 Dec 30;24(24):3697-714. doi: 10.1002/sim.2389.